Similar articles for PMID: 38499379

Year	Number of Results
2011	1
2013	1
2014	7
2015	7
2016	9
2017	15
2018	9
2019	8
2020	10
2021	14
2022	13
2023	11
2024	10
2025	3
2026	0

1

Young J, Lee E, Lindblad AJ, Falk J. Young J, et al. Can Fam Physician. 2024 Mar;70(3):183-184. doi: 10.46747/cfp.7003183. Can Fam Physician. 2024. PMID: 38499379 Free PMC article. No abstract available.

2

Orexin Receptor Antagonists and Insomnia.

Wu X, Xue T, Chen Z, Wang Z, Chen G. Wu X, et al. Curr Psychiatry Rep. 2022 Oct;24(10):509-521. doi: 10.1007/s11920-022-01357-w. Epub 2022 Aug 16. Curr Psychiatry Rep. 2022. PMID: 35972717 Review.

3

Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs.

Kumar A, Chanana P, Choudhary S. Kumar A, et al. Pharmacol Rep. 2016 Apr;68(2):231-42. doi: 10.1016/j.pharep.2015.09.002. Epub 2015 Sep 28. Pharmacol Rep. 2016. PMID: 26922522 Review.

4

Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.

Roecker AJ, Cox CD, Coleman PJ. Roecker AJ, et al. J Med Chem. 2016 Jan 28;59(2):504-30. doi: 10.1021/acs.jmedchem.5b00832. Epub 2015 Sep 15. J Med Chem. 2016. PMID: 26317591 Review.

5

Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities.

Carpi M, Palagini L, Fernandes M, Calvello C, Geoffroy PA, Miniati M, Pini S, Gemignani A, Mercuri NB, Liguori C. Carpi M, et al. Neuropharmacology. 2024 Mar 1;245:109815. doi: 10.1016/j.neuropharm.2023.109815. Epub 2023 Dec 17. Neuropharmacology. 2024. PMID: 38114045 Free article. Review.

6

Orexin, Sleep, Sympathetic Neural Activity, and Cardiovascular Function.

Bigalke JA, Shan Z, Carter JR. Bigalke JA, et al. Hypertension. 2022 Dec;79(12):2643-2655. doi: 10.1161/HYPERTENSIONAHA.122.19796. Epub 2022 Sep 23. Hypertension. 2022. PMID: 36148653 Free PMC article. Review.

7

Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.

Mahoney CE, Mochizuki T, Scammell TE. Mahoney CE, et al. Sleep. 2020 Jun 15;43(6):zsz302. doi: 10.1093/sleep/zsz302. Sleep. 2020. PMID: 31830270 Free PMC article.

8

Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment.

Palagini L, Geoffroy PA, Balestrieri M, Miniati M, Biggio G, Liguori C, Menicucci D, Ferini-Strambi L, Nobili L, Riemann D, Gemignani A. Palagini L, et al. J Sleep Res. 2023 Aug;32(4):e13825. doi: 10.1111/jsr.13825. Epub 2023 Feb 14. J Sleep Res. 2023. PMID: 36786121 Review.

9

A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia.

Ziemichód W, Grabowska K, Kurowska A, Biała G. Ziemichód W, et al. Molecules. 2022 Sep 16;27(18):6041. doi: 10.3390/molecules27186041. Molecules. 2022. PMID: 36144776 Free PMC article. Review.

10

The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.

Coleman PJ, Gotter AL, Herring WJ, Winrow CJ, Renger JJ. Coleman PJ, et al. Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:509-533. doi: 10.1146/annurev-pharmtox-010716-104837. Annu Rev Pharmacol Toxicol. 2017. PMID: 27860547 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 38499379

101 results

Results by year